Tax Incentives To Spur Innovation: BIO's "Big Ideas" Beyond FDA
You may also be interested in...
FDA Approval Standards Need To Be Relaxed, Venture Capitalists Say
FDA should accept “a reasonable likelihood of patient benefit” as the appropriate standard for approving therapies for unmet medical needs, the National Venture Capital Association and its Medical Innovation & Competitiveness Coalition contend.
FDA Approval Standards Need To Be Relaxed, Venture Capitalists Say
FDA should accept “a reasonable likelihood of patient benefit” as the appropriate standard for approving therapies for unmet medical needs, the National Venture Capital Association and its Medical Innovation & Competitiveness Coalition contend.